A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Colon | Rectum
What is the purpose of this trial?
This phase II trial studies how well savolitinib works in treating participants with MET amplified colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial withNational Cancer Institute
- Start Date06/25/2019
- End Date09/29/2019
- Last Updated06/27/2019
- Study HIC#2000025224